Targeting Tumor-Intrinsic Immunosuppressive Mechanisms to Enhance Efficacy of Immune Checkpoint Blockade in Lung Cancer
Abstract
This project addresses LCRP overarching challenges of understanding the molecular mechanisms of initiation and progression to clinically significant lung cancer, and identification of innovative strategies for prevention and treatment of lung cancer. Lung cancer is highly prevalent in both veterans and active-duty personnel due to exposures to mutagens in industrial substances, cigarette smoke, asbestos bearing materials, and battlefield air pollution. The cost of lung cancer to the VA has been suggested to be greater than $1 billion a year. This study will mechanistically dissect the IRE1XBP1 axis that constitutes a major immunosuppressive barrier that limits the efficacy of checkpoint blockade in NSCLC. Targeting the IRE1 has the immense potential to enhance the efficacy of PD-1 inhibition so that a larger cohort of NSCLC patients benefit.
Document Details
- Document Type
- Technical Report
- Publication Date
- Nov 01, 2022
- Accession Number
- AD1199167
Entities
People
- Vivek Mittal
Organizations
- Cornell University